European Delphi panel to build consensus on tapering and discontinuing thrombopoietin receptor agonists in immune thrombocytopenia

References

• Kistangari G, McCrae KR. Immune thrombocytopenia. Hematol Oncol Clin North Am. 2013;27(3):495–8. doi:10.1016/j.hoc.2013.03.001.
   PubMed Web of Science ®Google Scholar
• Kohli R, Chaturvedi S. Epidemiology and clinical manifestations of immune thrombocytopenia. Hämostaseologie. 2019;39(3):238–249. doi:10.1055/s-0039-1683416.
   PubMed Web of Science ®Google Scholar
• Trotter P, Hill QA. Immune thrombocytopenia: improving quality of life and patient outcomes. Pat Relat Outcome Meas. 2018;9:369. doi:10.2147/PROM.S140932.
   Web of Science ®Google Scholar
• European Medicines Agency. Guideline on the clinical development of medicinal products intended for the treatment of chronic primary immune thrombocytopenia. Oncology Working Party, editor. London, UK; 2014.
   Google Scholar
• Moulis G, Palmaro A, Montastruc J-L, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood. 2014;124(22):3308–3315. doi:10.1182/blood-2014-05-578336.
   PubMed Web of Science ®Google Scholar
• Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017;129(21):2829–2835. doi:10.1182/blood-2017-03-754119.
   PubMed Web of Science ®Google Scholar
• Cooper N, Hill QA, Grainger J, Westwood J-P, Bradbury C, Provan D, Thachil J, Ramscar N, Roy A. Tapering and discontinuation of thrombopoietin receptor agonist therapy in patients with immune thrombocytopenia: results from a modified Delphi panel. Acta Haematol. 2021;144(4):418–426. doi:10.1159/000510676.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Mahmud SN, Brigstocke SL, Torneten SM. Tapering eltrombopag in patients with chronic ITP: how successful is this and in whom does it work? Blood. 2015;126(23):1054. doi:10.1182/blood.V126.23.1054.1054.
   Web of Science ®Google Scholar
• Khellaf M, Michel M, Quittet P, Viallard J-F, Alexis M, Roudot-Thoraval F, Cheze S, Durand J-M, Lefrère F, Galicier L, et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood. 2011;118(16):4338–4345. doi:10.1182/blood-2011-03-340166.
   PubMed Web of Science ®Google Scholar
• Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013;121(3):537–545. doi:10.1182/blood-2012-04-425512.
   PubMed Web of Science ®Google Scholar
• Leven E, Miller A, Boulad N, Haider A, Bussel JB. Successful discontinuation of eltrombopag treatment in patients with chronic ITP. Blood. 2012;120(21):1085. doi:10.1182/blood.V120.21.1085.1085.
   Web of Science ®Google Scholar
• Rodeghiero F, Carli G. Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists. Ann Hematol. 2017;96(9):1421–1434. doi:10.1007/s00277-017-2953-6.
   PubMed Web of Science ®Google Scholar
• Carpenedo M, Baldacci E, Baratè C, Borchiellini A, Buccisano F, Calvaruso G, Chiurazzi F, Fattizzo B, Giuffrida G, Rossi E, et al. Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations. Ther Adv Hematol. 2021;12:20406207211048361. doi:10.1177/20406207211048361.
   Web of Science ®Google Scholar
• Cuker A, Despotovic JM, Grace RF, Kruse C, Lambert MP, Liebman HA, Lyons RM, McCrae KR, Pullarkat V, Wasser JS, et al. Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: expert consensus based on the RAND/UCLA modified Delphi panel method. Res Pract Thromb Haemost. 2021;5(1):69–80. doi:10.1002/rth2.12457.
   PubMed Web of Science ®Google Scholar
• Dalkey N, Helmer O. An experimental application of the Delphi method to the use of experts. Manage Sci. 1963;9(3):458–467. doi:10.1287/mnsc.9.3.458.
   Web of Science ®Google Scholar
• Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods: characteristics and guidelines for use. Am J Public Health. 1984;74(9):979–983. doi:10.2105/AJPH.74.9.979.
   PubMed Web of Science ®Google Scholar
• Rowe G, Wright G. Expert opinions in forecasting: the role of the Delphi technique. In: Scott Armstrong J, editor. Principles of forecasting. New York: Springer New York; 2001. p. 125–144.
   Google Scholar
• Furniss D, Randell R, O’Kane AA, Taneva S, Mentis H, Blandford A. Fieldwork for healthcare: guidance for investigating human factors in computing systems. Synth Lect Assistive Rehabil Health Preserving Technol. 2014;3(2):1–146.
   Google Scholar
• González-López TJ, Sánchez-González B, Pascual C, Arefi M, de Cabo E, Alonso A, Martín-Salces M, Jiménez-Bárcenas R, Calbacho M, Galan P, et al. Sustained response after discontinuation of short- and medium-term treatment with eltrombopag in patients with immune thrombocytopenia. Platelets. 2015;26(1):83–86. doi:10.3109/09537104.2013.870987.
   PubMed Web of Science ®Google Scholar
• Rashidi A, Blinder M. Combination therapy in relapsed or refractory chronic immune thrombocytopenia: a case report and literature review. J Clin Pharm Therap. 2016;41(5):453–458. doi:10.1111/jcpt.12421.
   PubMed Web of Science ®Google Scholar
• Ghadaki B, Nazi I, Kelton JG, Arnold DM. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion. 2013;53(11):2807–2812. doi:10.1111/trf.12139.
   PubMed Web of Science ®Google Scholar
• Iino M, Sakamoto Y, Sato T. Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice. Int J Hematol. 2020;112(2):159–168. doi:10.1007/s12185-020-02893-y.
   PubMed Web of Science ®Google Scholar
• González‐López TJ, Pascual C, Álvarez‐román MT, Fernández-Fuertes F, Sánchez-González B, Caparrós I, Jarque I, Mingot-Castellano ME, Hernández-Rivas JA, Martín-Salces M, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol. 2015;90(3):E40–43. doi:10.1002/ajh.23900.
   PubMed Web of Science ®Google Scholar
• Červinek L, Mayer J, Doubek M. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults. Int J Hematol. 2015;102(1):7–11. doi:10.1007/s12185-015-1793-1.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang M, Du X, Cheng Y, Cheng G. Safety and efficacy of eltrombopag plus pulsed dexamethasone as first‐line therapy for immune thrombocytopenia. Brit J Haematol. 2020;189(2):369–378. doi:10.1111/bjh.16327.
   PubMed Web of Science ®Google Scholar
• Wong RS, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, Bussel JB. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017;130(23):2527–2536. doi:10.1182/blood-2017-04-748707.
   PubMed Web of Science ®Google Scholar
• Zaja F, Carpenedo M, Baratè C, Borchiellini A, Chiurazzi F, Finazzi G, Lucchesi A, Palandri F, Ricco A, Santoro C, et al. Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: real-world recommendations. Blood Rev. 2020;41:100647. doi:10.1016/j.blre.2019.100647.
   PubMed Web of Science ®Google Scholar
• Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, Ghanima W, Godeau B, González-López TJ, Grainger J, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780–3817. doi:10.1182/bloodadvances.2019000812.
   PubMed Web of Science ®Google Scholar
• Taylor E. We agree, don’t we? The Delphi method for health environments research. HERD. 2020;13(1):11–23. doi:10.1177/1937586719887709.
   PubMedGoogle Scholar
• Gonzalez-Lopez TJ, Fernandez-Fuertes F, Izquierdo MCP, Caparros I, Bernat S, Pastoriza C, Martínez-Badas MP, Olivera PE, Caballero G, Hernandez-Rivas JA, et al. Long term discontinuation of eltrombopag after remission in primary immune thrombocytopenia: 8-year follow-up data from 15 Spanish centers. Blood. 2019;134(Supplement_1):2352. doi:10.1182/blood-2019-129274.
   Google Scholar
• Fowler FJ Jr, Levin CA, Sepucha KR. Informing and involving patients to improve the quality of medical decisions. Health Aff. 2011;30(4):699–706. doi:10.1377/hlthaff.2011.0003.
   Web of Science ®Google Scholar
• Hawley ST, Morris AM. Cultural challenges to engaging patients in shared decision making. Patient Educ Counsel. 2017;100(1):18–24. doi:10.1016/j.pec.2016.07.008.
   PubMed Web of Science ®Google Scholar
• Song F, Al-Samkari H. Management of adult patients with immune thrombocytopenia (ITP): a review on current guidance and experience from clinical practice. J Blood Med. 2021;12:653. doi:10.2147/JBM.S259101.
   PubMed Web of Science ®Google Scholar
• Thachil J, Bagot C, Bradbury C, Cooper N, Lester W, Grainger JD, Lowe G, Evans G, Talks K, Sibson K, et al. A United Kingdom Immune Thrombocytopenia (ITP) forum review of practice: thrombopoietin receptor agonists. Brit J Haematol. 2018;180(4):591–594. doi:10.1111/bjh.14395.
   PubMed Web of Science ®Google Scholar
• Mahevas M, Guillet S, Viallard J-F, Gobert D, Malphettes M, Cheze S, Lefrere F, Audia S, Bonnotte B, Lambotte O, et al. Rate of prolonged response after stopping thrombopoietin-receptor agonists treatment in primary immune thrombocytopenia (ITP): results from a nationwide prospective multicenter interventional study (STOPAGO). Blood. 2021;138(Supplement 1):583. doi:10.1182/blood-2021-152767.
   Google Scholar
• Mahévas M, Fain O, Ebbo M, Roudot-Thoraval F, Limal N, Khellaf M, Schleinitz N, Bierling P, Languille L, Godeau B, et al. The temporary use of thrombopoietin‐receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Brit J Haematol. 2014;165(6):865–869. doi:10.1111/bjh.12888.
   PubMed Web of Science ®Google Scholar
• Lucchini E, Palandri F, Volpetti S, Vianelli N, Auteri G, Rossi E, Patriarca A, Carli G, Barcellini W, Tosi P, et al. Eltrombopag as second line therapy in adult patients with primary immune thrombocytopenia (ITP) in attempt to achieve long-term remission. preliminary analysis of a phase ii, multicenter, prospective study by gimema group (the ESTIT study). Blood. 2018;132(Supplement 1):1135. doi:10.1182/blood-2018-99-113314.
   Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–2393. doi:10.1182/blood-2008-07-162503.
   PubMed Web of Science ®Google Scholar
• Vogel C, Zwolinsky S, Griffiths C, Hobbs M, Henderson E, Wilkins E. A Delphi study to build consensus on the definition and use of big data in obesity research. Int J Obesity. 2019 Dec 1;43(12):2573–2586. doi:10.1038/s41366-018-0313-9.
   PubMed Web of Science ®Google Scholar